|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:chemical_compound
gptkb:antineoplastic_agent
|
|
gptkbp:affects
|
monocytes
lymphocytes
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01BB04
|
|
gptkbp:CASNumber
|
gptkb:4291-63-8
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
active infection
|
|
gptkbp:discoveredBy
|
gptkb:Dennis_A._Carson
|
|
gptkbp:eliminationHalfLife
|
5-20 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasInChIKey
|
KQEBTUIZQZVEMJ-NNYOXOHSSA-N
|
|
gptkbp:hasMolecularFormula
|
C10H12ClN5O3
|
|
gptkbp:hasSMILES
|
Clc1ncnc2c1ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O
|
|
gptkbp:hasUNII
|
8M6SF1OZ1Z
|
|
gptkbp:is_a_prodrug_of
|
2-chloroadenine arabinoside triphosphate
|
|
gptkbp:is_administered_as
|
gptkb:tablet
infusion
|
|
gptkbp:is_cytotoxic_to
|
monocytes
lymphocytes
leukemic cells
|
|
gptkbp:is_on_the_WHO_Model_List_of_Essential_Medicines
|
true
|
|
gptkbp:IUPACName
|
gptkb:2-chloro-2'-deoxyadenosine
|
|
gptkbp:KEGGID
|
D00247
|
|
gptkbp:mechanismOfAction
|
inhibits DNA synthesis
|
|
gptkbp:meltingPoint
|
227-231°C
|
|
gptkbp:metabolism
|
purine nucleoside phosphorylase
|
|
gptkbp:PubChem_CID
|
1942
2019
DB00242
CHEBI:4021
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
immunosuppression
infections
myelosuppression
|
|
gptkbp:synonym
|
gptkb:cladribine
|
|
gptkbp:usedFor
|
gptkb:hairy_cell_leukemia
multiple sclerosis
|
|
gptkbp:was_first_synthesized_in
|
1970s
|
|
gptkbp:bfsParent
|
gptkb:Mavenclad
gptkb:cladribine
gptkb:Cladribine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
2-chlorodeoxyadenosine
|